Crossmark

Costos de la administración intravenosa vs. subcutánea del trastuzumab en pacientes peruanas con cáncer de mama HER2 positivo. Un análisis observacional de los costos directos e indirectos

Crossref DOI link: https://doi.org/10.1016/j.jhqr.2021.10.008

Published Print: 2022-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Olivera Changra, Henry

Robles Díaz, José Fernando
License Information

Text and Data Mining valid from 2022-05-01
More Information

This article is maintained by: Elsevier

Article Title: Costos de la administración intravenosa vs. subcutánea del trastuzumab en pacientes peruanas con cáncer de mama HER2 positivo. Un análisis observacional de los costos directos e indirectos

Journal Title: Journal of Healthcare Quality Research

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jhqr.2021.10.008

Content Type: article

Copyright: © 2021 FECA. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below